2018 AACR: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoantigen Burden and Tumor Escape Mechanisms for Clinical Treatment

Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in identifying biomarkers and mechanisms that influence immunotherapy effectiveness. In this study, we characterize the immuno-genomics of tumors from a series of melanoma patients that have received anti-PD-1 checkpoint inhibitors to assess potential factors influencing response.

Download
2019-01-07T10:17:15+00:00